JP2025077045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025077045A5 JP2025077045A5 JP2025003471A JP2025003471A JP2025077045A5 JP 2025077045 A5 JP2025077045 A5 JP 2025077045A5 JP 2025003471 A JP2025003471 A JP 2025003471A JP 2025003471 A JP2025003471 A JP 2025003471A JP 2025077045 A5 JP2025077045 A5 JP 2025077045A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- sequence
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902343 | 2019-07-02 | ||
| AU2019902343A AU2019902343A0 (en) | 2019-07-02 | Antibodies | |
| JP2021578267A JP7678768B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
| PCT/AU2020/050689 WO2021000017A1 (en) | 2019-07-02 | 2020-07-02 | Antibodies against caix with reduced affinity for the neonatal fc receptor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578267A Division JP7678768B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025077045A JP2025077045A (ja) | 2025-05-16 |
| JP2025077045A5 true JP2025077045A5 (cg-RX-API-DMAC7.html) | 2025-05-23 |
Family
ID=74100150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578267A Active JP7678768B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
| JP2025003471A Pending JP2025077045A (ja) | 2019-07-02 | 2025-01-09 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578267A Active JP7678768B2 (ja) | 2019-07-02 | 2020-07-02 | 新生児ｆｃ受容体に対する低下した親和性を有する、ｃａｉｘに対する抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220331457A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3994176A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7678768B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220057516A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114502596A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026651A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3141457A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2021003561A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289524A (cg-RX-API-DMAC7.html) |
| MA (1) | MA56467A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021015670A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021000017A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4294845A4 (en) * | 2021-02-22 | 2026-01-07 | Abdera Therapeutics Inc | Immunoconjugates for targeted radioisotope therapy |
| KR20240049818A (ko) * | 2021-08-17 | 2024-04-17 | 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 | 병용 방사선요법 |
| US20240359144A1 (en) * | 2021-09-01 | 2024-10-31 | Telix Pharmaceuticals (Innovations) Pty Ltd | Aggregate separation method |
| EP4536296A1 (en) * | 2022-06-09 | 2025-04-16 | Telix Pharmaceuticals (Innovations) Pty Ltd | Combination therapy |
| CN121293357A (zh) | 2022-08-22 | 2026-01-09 | 雅博得乐医疗公司 | Dll3结合分子及其用途 |
| JP2026510493A (ja) * | 2023-03-09 | 2026-04-07 | テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド | 多機能抗体 |
| CN122270294A (zh) * | 2023-12-01 | 2026-06-23 | 泰利斯制药(创新)有限公司 | 新型放射性标记抗体 |
| TW202611088A (zh) | 2024-07-23 | 2026-03-16 | 美商雅博得樂醫療公司 | 5t4結合多肽及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1358318T3 (da) * | 2001-02-07 | 2007-01-02 | Wilex Ag | Hybridomcellelinje G250 og dens anvendelse til frembringelse af monoklonale antistoffer |
| US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1979379B1 (en) * | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| WO2008091798A2 (en) * | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Optimized ca9 antibodies and methods of using the same |
| MX2011012047A (es) * | 2009-05-13 | 2011-12-14 | Genzyme Corp | Inmunoglobulinas humanas anti-cd52. |
| CN102775500A (zh) * | 2012-08-03 | 2012-11-14 | 郑骏年 | 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途 |
| TW201920285A (zh) | 2013-04-29 | 2019-06-01 | 瑞士商赫孚孟拉羅股份公司 | 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途 |
| CA2904806C (en) * | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| CA2926215A1 (en) * | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
| CN110903398B (zh) * | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| CN110981957B (zh) * | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| EP4086285A1 (en) * | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| EP3502139A1 (en) * | 2017-12-19 | 2019-06-26 | Philogen S.p.A. | Antibodies to tumour antigens |
-
2020
- 2020-07-02 MA MA056467A patent/MA56467A/fr unknown
- 2020-07-02 MX MX2021015670A patent/MX2021015670A/es unknown
- 2020-07-02 CA CA3141457A patent/CA3141457A1/en active Pending
- 2020-07-02 KR KR1020227002842A patent/KR20220057516A/ko active Pending
- 2020-07-02 BR BR112021026651A patent/BR112021026651A2/pt unknown
- 2020-07-02 CN CN202080054196.6A patent/CN114502596A/zh active Pending
- 2020-07-02 EP EP20834781.5A patent/EP3994176A4/en active Pending
- 2020-07-02 US US17/622,341 patent/US20220331457A1/en active Pending
- 2020-07-02 JP JP2021578267A patent/JP7678768B2/ja active Active
- 2020-07-02 WO PCT/AU2020/050689 patent/WO2021000017A1/en not_active Ceased
-
2021
- 2021-12-29 CL CL2021003561A patent/CL2021003561A1/es unknown
- 2021-12-30 IL IL289524A patent/IL289524A/en unknown
-
2024
- 2024-04-25 US US18/646,281 patent/US20240342323A1/en active Pending
- 2024-11-04 CL CL2024003365A patent/CL2024003365A1/es unknown
-
2025
- 2025-01-09 JP JP2025003471A patent/JP2025077045A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025069166A5 (cg-RX-API-DMAC7.html) | ||
| JP2022540385A5 (cg-RX-API-DMAC7.html) | ||
| JP7828375B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| JP2022540384A5 (cg-RX-API-DMAC7.html) | ||
| CN102596258B (zh) | 用于制备放射性免疫缀合物的方法 | |
| US20240342323A1 (en) | Antibodies against caix with reduced affinity for the neonatal fc receptor | |
| US11981741B2 (en) | Humanized anti-CD45 antibodies | |
| JP2009268470A (ja) | 抗体分子を用いての腫瘍脈管系の選択的標的化 | |
| CA3069140A1 (en) | Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy | |
| JP7759348B2 (ja) | がんの治療のための抗ｂ７ｈ３抗体 | |
| CN100482285C (zh) | 放射性标记的抗纤连蛋白ed-b的抗体l19靶向肿瘤血管的制药用途 | |
| CN118159558A (zh) | 抗dll3抗体和其用途 | |
| WO2024055040A2 (en) | Humanized anti-cd45 antibodies | |
| WO2022268225A1 (zh) | CD8α结合多肽及其用途 | |
| JP2021511068A (ja) | Ｃｅｎｔｒｉｎ−１に対する抗体、作製方法、及びその使用 | |
| ES2541907T3 (es) | Secuencias de nucleótidos y proteínas de un anticuerpo dirigido frente a un epítopo común para ferritínas humanas ácidas y básicas, anticuerpos monoclonales o moléculas semejantes a anticuerpo que comprenden estas secuencias y uso de éstos. | |
| CA3228414A1 (en) | Anti-cd33 antibodies and uses thereof | |
| HK40066936A (en) | Antibodies against caix with reduced affinity for the neonatal fc receptor | |
| TW202600607A (zh) | Ｄｄｌ３結合免疫接合物及其用途 | |
| HK40066937A (en) | Antibodies for binding psma with reduced affinity for the neonatal fc receptor |